PACK Study: Prescribing Anticoagulation in Chronic Kidney Disease

What is the purpose of the research?
This study intends to explore the views of patients with kidney disease on blood-thinning drugs. The aim will be to develop a guide to help other kidney patients when making decisions about starting these treatments.

What would be required?
An online group discussion of 60-90 minutes will explore patients’ personal experiences. Things that may be discussed include what could have been improved upon within their treatment, and ideas of information that will be useful for others. This will conclude participants involvement.
A £30 M&S voucher would be available for taking part in this research.

What happens after the focus groups?
The ideas generated from these groups will be used to produce a guide for patients, with support from the patient co-applicant and the Manchester kidney patient research group. This will contain useful information and questions to pose to health professionals, supporting and encouraging kidney patients to ensure they make the best treatment decision for them.

Who are we looking for?
Kidney patients 18 years and over who were under the care of a kidney specialist when starting blood-thinning drugs. It doesn’t matter if you no longer take blood-thinning drugs. Blood-thinning drugs would include warfarin, apixaban, rivaroxaban and edoxaban. We intend to include between 20 and 30 kidney patients.

Who to contact if you are interested or would like more information
If you have any queries about the study or if you are interested in taking part then please contact the researcher Kathrine Parker. E-mail Kathrine.parker@postgrad.manchester.ac.uk or Kathrine.parker@mft.nhs.uk, before Friday December 17th.

Share this post

Share on facebook
Share on twitter
Share on linkedin
Share on pinterest
Share on print
Share on email
Skip to content